Incidence, treatment and outcome of abdominal metastases in extremity soft tissue sarcoma: Results from a multi-centre study.
abdominal metastasis
soft tissue sarcoma
survival
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
09
11
2019
accepted:
16
01
2020
pubmed:
1
2
2020
medline:
7
3
2020
entrez:
1
2
2020
Statut:
ppublish
Résumé
Abdominal metastases (AM) from soft tissue sarcoma (STS) are rare and prognosis is poor. The aims of the study were to (a) identify risk factors for the development of AM and to (b) investigate the outcome of AM-patients. Seven-hundred-sixty-nine STS-patients with localised disease at diagnosis treated at three tumour centres (2000-2016) were retrospectively included (409 males; mean age, 55.6 years [range, 8-96 years]; median follow-up, 4.1 years [interquartile-range, 2.5-6.6 years]). Two-hundred-two patients (26.3%) developed secondary metastases, and 24 of them AM (3.1%). Ten patients developed first AM (FAM) after a mean of 2.4 years and 14 patients late AM (LAM, after being diagnosed with metastases to other sites) after a mean of 2.0 years. Patients with liposarcoma had a significantly higher risk of developing AM (P = .007), irrespective of grading. There was no difference in post-metastasis-survival (PMS) between patients with AM at any time point and those with metastases to other sites (P = .585). Patients with LAM or FAM showed no difference in post-abdominal-metastasis-survival (P = .884). Survival in patients with AM is poor, irrespective of whether they develop secondarily to other metastases or not. Patients at high-risk of AM (ie, liposarcoma) may be followed-up regularly by abdominal-ultrasound/CT.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Abdominal metastases (AM) from soft tissue sarcoma (STS) are rare and prognosis is poor. The aims of the study were to (a) identify risk factors for the development of AM and to (b) investigate the outcome of AM-patients.
METHODS
METHODS
Seven-hundred-sixty-nine STS-patients with localised disease at diagnosis treated at three tumour centres (2000-2016) were retrospectively included (409 males; mean age, 55.6 years [range, 8-96 years]; median follow-up, 4.1 years [interquartile-range, 2.5-6.6 years]).
RESULTS
RESULTS
Two-hundred-two patients (26.3%) developed secondary metastases, and 24 of them AM (3.1%). Ten patients developed first AM (FAM) after a mean of 2.4 years and 14 patients late AM (LAM, after being diagnosed with metastases to other sites) after a mean of 2.0 years. Patients with liposarcoma had a significantly higher risk of developing AM (P = .007), irrespective of grading. There was no difference in post-metastasis-survival (PMS) between patients with AM at any time point and those with metastases to other sites (P = .585). Patients with LAM or FAM showed no difference in post-abdominal-metastasis-survival (P = .884).
CONCLUSIONS
CONCLUSIONS
Survival in patients with AM is poor, irrespective of whether they develop secondarily to other metastases or not. Patients at high-risk of AM (ie, liposarcoma) may be followed-up regularly by abdominal-ultrasound/CT.
Identifiants
pubmed: 32003475
doi: 10.1002/jso.25856
pmc: PMC7065201
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
605-611Informations de copyright
© 2020 The Authors. Journal of Surgical Oncology published by Wiley Periodicals, Inc.
Références
Langenbecks Arch Surg. 2011 Oct;396(7):1083-91
pubmed: 21739304
Skeletal Radiol. 2008 Mar;37(3):251-8
pubmed: 18097662
Lancet Oncol. 2016 May;17(5):671-80
pubmed: 27068860
Bone Joint Res. 2015 Mar;4(3):45-9
pubmed: 25792705
J Transl Med. 2014 Jun 20;12:176
pubmed: 24950699
Eur J Surg Oncol. 2019 Feb;45(2):242-248
pubmed: 30031674
Curr Opin Oncol. 2004 Jul;16(4):328-32
pubmed: 15187887
Cancer. 2012 Sep 1;118(17):4235-43
pubmed: 22252777
J Surg Oncol. 2004 Sep 1;87(3):116-20
pubmed: 15334637
J Orthop Sci. 2000;5(5):463-9
pubmed: 11180903
J Natl Compr Canc Netw. 2018 May;16(5):536-563
pubmed: 29752328
Cancer. 2014 Nov 1;120(21):3361-9
pubmed: 25042799
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv267
pubmed: 30188977
Cancer. 2000 Jan 15;88(2):364-8
pubmed: 10640969
Ann Diagn Pathol. 2003 Oct;7(5):306-9
pubmed: 14571434
Clin Orthop Relat Res. 2009 Nov;467(11):2838-44
pubmed: 19636646
Eur J Surg Oncol. 2016 Jun;42(6):899-906
pubmed: 27107792
Eur J Cancer. 2017 Sep;83:313-323
pubmed: 28797949
Ann Surg Oncol. 2017 Jun;24(6):1596-1605
pubmed: 28108827
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Clin Sarcoma Res. 2016 Nov 15;6:20
pubmed: 27891213
JBR-BTR. 2011 Sep-Oct;94(5):287-9
pubmed: 22191294
J Surg Oncol. 2020 Mar;121(4):605-611
pubmed: 32003475
Dig Endosc. 2010 Apr;22(2):137-9
pubmed: 20447209
Ann Oncol. 2010 May;21(5):1106-11
pubmed: 19858086
Br J Cancer. 2014 May 13;110(10):2420-6
pubmed: 24736584
Bone Joint J. 2018 Feb;100-B(2):262-268
pubmed: 29437071
J Clin Oncol. 1985 Mar;3(3):353-66
pubmed: 3973646